Ensem Therapeutics, Inc. (ENSEM), a clinical-stage, oncology-focused biopharmaceutical company, today announced that the first patient has been dosed with ETX-636 in China at Fudan University Shanghai ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results